Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis.


Journal

The Lancet. Public health
ISSN: 2468-2667
Titre abrégé: Lancet Public Health
Pays: England
ID NLM: 101699003

Informations de publication

Date de publication:
05 2021
Historique:
received: 17 08 2020
revised: 12 01 2021
accepted: 14 01 2021
pubmed: 30 3 2021
medline: 6 5 2021
entrez: 29 3 2021
Statut: ppublish

Résumé

People who inject drugs (PWID) are at increased risk for HIV and hepatitis C virus (HCV) infection and also have high levels of homelessness and unstable housing. We assessed whether homelessness or unstable housing is associated with an increased risk of HIV or HCV acquisition among PWID compared with PWID who are not homeless or are stably housed. In this systematic review and meta-analysis, we updated an existing database of HIV and HCV incidence studies published between Jan 1, 2000, and June 13, 2017. Using the same strategy as for this existing database, we searched MEDLINE, Embase, and PsycINFO for studies, including conference abstracts, published between June 13, 2017, and Sept 14, 2020, that estimated HIV or HCV incidence, or both, among community-recruited PWID. We only included studies reporting original results without restrictions to study design or language. We contacted authors of studies that reported HIV or HCV incidence, or both, but did not report on an association with homelessness or unstable housing, to request crude data and, where possible, adjusted effect estimates. We extracted effect estimates and pooled data using random-effects meta-analyses to quantify the associations between recent (current or within the past year) homelessness or unstable housing compared with not recent homelessness or unstable housing, and risk of HIV or HCV acquisition. We assessed risk of bias using the Newcastle-Ottawa Scale and between-study heterogeneity using the I We identified 14 351 references in our database search, of which 392 were subjected to full-text review alongside 277 studies from our existing database. Of these studies, 55 studies met inclusion criteria. We contacted the authors of 227 studies that reported HIV or HCV incidence in PWID but did not report association with the exposure of interest and obtained 48 unpublished estimates from 21 studies. After removal of duplicate data, we included 37 studies with 70 estimates (26 for HIV; 44 for HCV). Studies originated from 16 countries including in North America, Europe, Australia, east Africa, and Asia. Pooling unadjusted estimates, recent homelessness or unstable housing was associated with an increased risk of acquiring HIV (crude relative risk [cRR] 1·55 [95% CI 1·23-1·95; p=0·0002]; I Homelessness and unstable housing are associated with increased risk of HIV and HCV acquisition among PWID. Our findings support the development of interventions that simultaneously address homelessness and unstable housing and HIV and HCV transmission in this population. National Institute for Health Research, National Institute on Drug Abuse, National Institute of Allergy and Infectious Diseases, and Commonwealth Scholarship Commission.

Sections du résumé

BACKGROUND
People who inject drugs (PWID) are at increased risk for HIV and hepatitis C virus (HCV) infection and also have high levels of homelessness and unstable housing. We assessed whether homelessness or unstable housing is associated with an increased risk of HIV or HCV acquisition among PWID compared with PWID who are not homeless or are stably housed.
METHODS
In this systematic review and meta-analysis, we updated an existing database of HIV and HCV incidence studies published between Jan 1, 2000, and June 13, 2017. Using the same strategy as for this existing database, we searched MEDLINE, Embase, and PsycINFO for studies, including conference abstracts, published between June 13, 2017, and Sept 14, 2020, that estimated HIV or HCV incidence, or both, among community-recruited PWID. We only included studies reporting original results without restrictions to study design or language. We contacted authors of studies that reported HIV or HCV incidence, or both, but did not report on an association with homelessness or unstable housing, to request crude data and, where possible, adjusted effect estimates. We extracted effect estimates and pooled data using random-effects meta-analyses to quantify the associations between recent (current or within the past year) homelessness or unstable housing compared with not recent homelessness or unstable housing, and risk of HIV or HCV acquisition. We assessed risk of bias using the Newcastle-Ottawa Scale and between-study heterogeneity using the I
FINDINGS
We identified 14 351 references in our database search, of which 392 were subjected to full-text review alongside 277 studies from our existing database. Of these studies, 55 studies met inclusion criteria. We contacted the authors of 227 studies that reported HIV or HCV incidence in PWID but did not report association with the exposure of interest and obtained 48 unpublished estimates from 21 studies. After removal of duplicate data, we included 37 studies with 70 estimates (26 for HIV; 44 for HCV). Studies originated from 16 countries including in North America, Europe, Australia, east Africa, and Asia. Pooling unadjusted estimates, recent homelessness or unstable housing was associated with an increased risk of acquiring HIV (crude relative risk [cRR] 1·55 [95% CI 1·23-1·95; p=0·0002]; I
INTERPRETATION
Homelessness and unstable housing are associated with increased risk of HIV and HCV acquisition among PWID. Our findings support the development of interventions that simultaneously address homelessness and unstable housing and HIV and HCV transmission in this population.
FUNDING
National Institute for Health Research, National Institute on Drug Abuse, National Institute of Allergy and Infectious Diseases, and Commonwealth Scholarship Commission.

Identifiants

pubmed: 33780656
pii: S2468-2667(21)00013-X
doi: 10.1016/S2468-2667(21)00013-X
pmc: PMC8097637
pii:
doi:

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e309-e323

Subventions

Organisme : NIDA NIH HHS
ID : R21 DA046809
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_00004/03
Pays : United Kingdom
Organisme : NIDA NIH HHS
ID : R01 DA047952
Pays : United States
Organisme : NIDA NIH HHS
ID : U01 DA038886
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA033679
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI147490
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA037773
Pays : United States
Organisme : Medical Research Council
ID : MR/N00616X/1
Pays : United Kingdom

Investigateurs

Peter Cherutich (P)
Kora Debeck (K)
Paul Dietze (P)
Kostyantyn Dumchev (K)
Kanna Hayashi (K)
Margaret Hellard (M)
Matthew Hickman (M)
Vivian Hope (V)
Ali Judd (A)
Martin Kåberg (M)
Ann E Kurth (AE)
Pascale Leclerc (P)
Lisa Maher (L)
Shruti H Mehta (SH)
Kimberly A Page (KA)
Maria Prins (M)
Catherine S Todd (CS)
Steffanie A Strathdee (SA)

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests HF reports honoraria from MSD outside of the submitted work. JA reports grants from National Institutes of Health (NIH) during the conduct of the study. SSS reports grants from NIH during the conduct of the study, and grants from Gilead Sciences and Abbot Diagnostics outside of the submitted work. VS reports grants, personal fees, and non-financial support from Gilead Sciences and AbbVie and personal fees from Janssen outside of the submitted work. JGW reports grants from Gilead Sciences outside of the submitted work. All other authors declare no competing interests.

Références

Subst Use Misuse. 2009;44(2):139-62
pubmed: 19142817
J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):369-76
pubmed: 18176320
AIDS Behav. 2005 Sep;9(3):251-65
pubmed: 16088369
Hepatology. 2013 Nov;58(5):1598-609
pubmed: 23553643
JAMA. 1998 Nov 18;280(19):1690-1
pubmed: 9832001
J Infect Dis. 2010 Feb 1;201(3):378-85
pubmed: 20053137
J Urban Health. 2020 Dec;97(6):831-844
pubmed: 32901411
Am J Public Health. 2001 Jan;91(1):42-6
pubmed: 11189822
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
BMC Public Health. 2011 Aug 10;11:638
pubmed: 21831318
Int J Epidemiol. 2014 Feb;43(1):235-48
pubmed: 24374889
Thorax. 2018 Jun;73(6):557-564
pubmed: 29378859
Lancet Respir Med. 2020 Dec;8(12):1181-1191
pubmed: 32979308
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
PLoS One. 2018 Oct 3;13(10):e0204795
pubmed: 30281616
Acad Emerg Med. 2018 May;25(5):577-593
pubmed: 29223132
Health Soc Care Community. 2005 Jan;13(1):75-83
pubmed: 15717909
PLoS One. 2013 Nov 07;8(11):e80216
pubmed: 24244654
CMAJ. 2019 Apr 29;191(17):E462-E468
pubmed: 31036608
Public Health Rep. 2020 Jul/Aug;135(4):435-441
pubmed: 32516035
PLoS One. 2018 Aug 30;13(8):e0203262
pubmed: 30161255
Sex Transm Dis. 2016 Oct;43(10):648-55
pubmed: 27631361
Lancet Infect Dis. 2018 Dec;18(12):1397-1409
pubmed: 30385157
Euro Surveill. 2018 Nov;23(47):
pubmed: 30482265
Lancet Infect Dis. 2016 Dec;16(12):1385-1398
pubmed: 27665254
BMJ. 2012 Oct 03;345:e5945
pubmed: 23038795
PLoS One. 2013 Dec 16;8(12):e81715
pubmed: 24358123
Addiction. 2006 Oct;101(10):1499-508
pubmed: 16968352
Epidemiol Infect. 2009 Sep;137(9):1255-65
pubmed: 19224654
Harm Reduct J. 2013 Jun 21;10:11
pubmed: 23786848
BMJ. 2005 Jan 1;330(7481):24-5
pubmed: 15533854
J Infect Dis. 2017 May 15;215(10):1496-1505
pubmed: 28407106
Int J Drug Policy. 2019 Oct;72:69-76
pubmed: 31010749
Int J Drug Policy. 2009 May;20(3):193-201
pubmed: 19147339
Epidemiol Infect. 2004 Aug;132(4):699-708
pubmed: 15310172
Am J Epidemiol. 2002 Apr 1;155(7):645-53
pubmed: 11914192
Harm Reduct J. 2015 Oct 16;12:22
pubmed: 26472126
BMC Public Health. 2015 Feb 07;15:106
pubmed: 25884182
J Antimicrob Chemother. 2019 Nov 1;74(Suppl 5):v5-v16
pubmed: 31782503
Am J Epidemiol. 2011 May 1;173(9):1049-58
pubmed: 21362739
Drug Alcohol Rev. 2015 Jul;34(4):379-87
pubmed: 25787785
Eur J Public Health. 2011 Oct;21(5):613-9
pubmed: 20798184
Drug Alcohol Depend. 2009 Jan 1;99(1-3):176-82
pubmed: 18805655
Am J Drug Alcohol Abuse. 2004;30(1):129-53
pubmed: 15083558
Addiction. 2011 Nov;106(11):1978-88
pubmed: 21615585
Med Sci Monit. 2011 May;17(5):RA124-33
pubmed: 21525823
J Adolesc Health. 2014 Dec;55(6):830-4
pubmed: 25240449
Lancet HIV. 2020 Jun;7(6):e434-e442
pubmed: 32504576
Addiction. 2008 Oct;103(10):1593-603
pubmed: 18821870
Harm Reduct J. 2014 Feb 12;11:4
pubmed: 24520885
AIDS. 2000 Sep 8;14(13):2035-43
pubmed: 10997409
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
Lancet. 2017 Mar 4;389(10072):941-950
pubmed: 28271845
J Urban Health. 2013 Aug;90(4):699-716
pubmed: 22733170
J Addict Med. 2015 May-Jun;9(3):226-32
pubmed: 25961495
Vaccine. 2014 Sep 22;32(42):5460-7
pubmed: 25131726
Lancet Respir Med. 2020 May;8(5):447-449
pubmed: 32222165
Addiction. 2015 Apr;110(4):572-84
pubmed: 25582153
Lancet. 2001 May 5;357(9266):1397-401
pubmed: 11356437
Public Health Nutr. 2016 Aug;19(12):2204-12
pubmed: 26956477
Health Place. 2006 Mar;12(1):79-85
pubmed: 16243682
Lancet. 2018 Jan 20;391(10117):266-280
pubmed: 29137868
Addiction. 2007 Sep;102(9):1454-62
pubmed: 17697278
J Epidemiol Community Health. 2015 Jun;69(6):599-603
pubmed: 25870164
BMC Public Health. 2009 Jul 29;9:270
pubmed: 19640297
Lancet Glob Health. 2017 Dec;5(12):e1208-e1220
pubmed: 29074410
Lancet Gastroenterol Hepatol. 2019 Jun;4(6):435-444
pubmed: 30981685
Lancet. 2016 Sep 10;388(10049):1081-1088
pubmed: 27394647
AIDS. 2015 Mar 13;29(5):619-28
pubmed: 25715105
J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):420-7
pubmed: 26226249
BMC Public Health. 2012 Aug 09;12:632
pubmed: 22877418
J Viral Hepat. 2019 May;26(5):519-528
pubmed: 30422370
PLoS One. 2019 Sep 11;14(9):e0222186
pubmed: 31509571
Harm Reduct J. 2013 May 07;10:7
pubmed: 23651646
J Urban Health. 2018 Feb;95(1):99-110
pubmed: 29204843
AIDS Behav. 2018 Dec;22(12):3957-3961
pubmed: 29876756
Cochrane Database Syst Rev. 2017 Sep 18;9:CD012021
pubmed: 28922449
Int J Drug Policy. 2008 Dec;19(6):429-35
pubmed: 17962008
Lancet. 2016 Sep 17;388(10050):1228-48
pubmed: 27427455
J Subst Abuse Treat. 2009 Apr;36(3):306-12
pubmed: 18835681
Lancet. 2010 Jul 24;376(9737):268-84
pubmed: 20650523
HIV Med. 2020 Mar;21(3):142-162
pubmed: 31682060
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
J Epidemiol Community Health. 2009 Jan;63(1):81-6
pubmed: 18628270
Drug Alcohol Depend. 2013 Oct 1;132(3):457-65
pubmed: 23578590
J Viral Hepat. 2018 Dec;25(12):1452-1461
pubmed: 29998522
Public Health Rep. 2002;117 Suppl 1:S135-45
pubmed: 12435837
PLoS One. 2014 Aug 11;9(8):e104515
pubmed: 25110927
Lancet. 2018 Jan 20;391(10117):241-250
pubmed: 29137869

Auteurs

Chiedozie Arum (C)

Population Health Sciences, University of Bristol, Bristol, UK.

Hannah Fraser (H)

Population Health Sciences, University of Bristol, Bristol, UK.

Andreea Adelina Artenie (AA)

Population Health Sciences, University of Bristol, Bristol, UK.

Sandra Bivegete (S)

Population Health Sciences, University of Bristol, Bristol, UK.

Adam Trickey (A)

Population Health Sciences, University of Bristol, Bristol, UK.

Michel Alary (M)

Centre de recherche du CHU de Québec, Université Laval, Quebec City, QC, Canada; Département de médecine sociale et préventive, Université Laval, Quebec City, QC, Canada; Institut national de santé publique du Québec, Québec, QC, Canada.

Jacquie Astemborski (J)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Jennifer Iversen (J)

Kirby Institute for Infection and Immunity, UNSW Sydney, NSW, Australia.

Aaron G Lim (AG)

Population Health Sciences, University of Bristol, Bristol, UK.

Louis MacGregor (L)

Population Health Sciences, University of Bristol, Bristol, UK.

Meghan Morris (M)

Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.

Jason J Ong (JJ)

Population Health Sciences, University of Bristol, Bristol, UK; Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK.

Lucy Platt (L)

Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.

Rachel Sack-Davis (R)

Burnet Institute, Melbourne, VIC, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.

Daniela K van Santen (DK)

Burnet Institute, Melbourne, VIC, Australia; Department of Infectious Disease Research and Prevention, Public Health Service of Amsterdam, Amsterdam, Netherlands.

Sunil S Solomon (SS)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Vana Sypsa (V)

Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Jorge Valencia (J)

Harm Reduction Unit "SMASD", Department of Addictions and Mental Health, Madrid, Spain.

Wijnand Van Den Boom (W)

Burnet Institute, Melbourne, VIC, Australia.

Josephine G Walker (JG)

Population Health Sciences, University of Bristol, Bristol, UK.

Zoe Ward (Z)

Population Health Sciences, University of Bristol, Bristol, UK.

Jack Stone (J)

Population Health Sciences, University of Bristol, Bristol, UK. Electronic address: jack.stone@bristol.ac.uk.

Peter Vickerman (P)

Population Health Sciences, University of Bristol, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH